Why the study?
Does a lower left ventricular wall stress-mass-heart rate product (triple product) during antihypertensive treatment reduce cardiovascular events in hypertensive patients?
Population
905 participants from the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study
Comparison
Losartan-based antihypertensive treatment vs Atenolol-based antihypertensive treatment
Design
Cohort, Randomized treatment (losartan vs atenolol)
Follow-up
4.8 years
Authors
Loading...
Should not yet guide antihypertensive targets; leaves open independent prognostic value beyond BP in hypertension.
Does a lower left ventricular wall stress-mass-heart rate product (triple product) during antihypertensive treatment reduce cardiovascular events in hypertensive patients?
A lower left ventricular wall stress-mass-heart rate product during antihypertensive treatment is strongly associated with lower rates of cardiovascular death and MI, highlighting the importance of reducing myocardial oxygen demand.
Devereux et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: